Last reviewed 2026-04-20 · How we verify

Tachmalcor (detajmium)

Tachmalcor (generic name: detajmium) is a detajmium drug. It is currently in unknown development for Supraventricular arrhythmia, Ventricular arrhythmia.

Tachmalcor works by stabilizing cardiac ion channels to regulate abnormal heart rhythms.

Tachmalcor (detajmium) is a small molecule drug in the detajmium class, developed for the treatment of supraventricular and ventricular arrhythmias. Its exact mechanism of action is not well-documented, but it is believed to work by stabilizing cardiac ion channels. The commercial status of Tachmalcor is unclear, and it may be patented or have generic manufacturers available. Further research is needed to determine its safety profile and efficacy in clinical settings.

At a glance

Mechanism of action

Think of your heart like a muscle that needs to beat in a regular rhythm. Sometimes, this rhythm can get disrupted, leading to abnormal heartbeats. Tachmalcor helps to stabilize the channels that control these heartbeats, allowing them to return to a normal rhythm.

Approved indications

• Supraventricular arrhythmia
• Ventricular arrhythmia

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tachmalcor CI brief — competitive landscape report
• Tachmalcor updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Tachmalcor

Related

• Drug class: All detajmium drugs
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Supraventricular arrhythmia
• Indication: Drugs for Ventricular arrhythmia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing